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The role of lipids in renal disease: future challenges. Experi- lipids will have an added beneficial effect on reducing
mental studies have provided in vivo and in vitro data to sup- the rate of loss of renal function in human renal diseases.
port the notion that dyslipidemia contributes to glomerular Analysis of existing studies suggest that the use of these
and interstitial injury of the renal parenchyma. The 3-hydroxy-
agents, particularly the HMG-CoA reductase inhibitors,3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
will have additive effects to antihypertensive therapies.are a new class of lipid-lowering agents that have been exten-
sively studied during the past decade. These agents have sig- Since cardiovascular disease is intricately connected to
nificant effects on circulating lipids and both renal and vascular the presence of proteinuria/albuminuria and renal dis-
injury. New insights into the mechanisms of action of these ease, future attempts to modify dyslipidemia may have
agents have revealed an important effect on a variety of in-
substantial clinical benefits by reducing mortality ratesflammatory and fibrogenic processes that appear to have major
associated with renal as well as cardiovascular disease.implications for human renal and cardiovascular diseases.
DYSLIPIDEMIA AND RENAL DISEASE
Recent clinical data have suggested that dyslipidemia
Microalbuminuriais an important clinical abnormality seen in patients with
Urinary excretion of albumin above 30 mg/24 h or andiabetes mellitus and patients with essential hyperten-
albumin-to-creatinine ratio greater than 30, by conven-sion with microalbuminuria. It has been demonstrated
tion, has been termed microalbuminuria. It has long beenthat microalbuminuria in both of these groups of patients
recognized that excretion of increased amounts of albu-predicts the presence of a number of additional high risk
min is a highly significant predictor of those diabeticmetabolic abnormalities. The mechanisms involved in
patients that will develop progressive nephropathy [1–4].these abnormalities remain incompletely understood al-
Similarly, diabetic patients with microalbuminuria alsothough insulin resistance may have a central role. These
have increased risk for cardiovascular disease [5–7]. Re-individuals are at increased risk for cardiovascular dis-
cently, a similar association between microalbuminuriaease and increased cardiovascular mortality. There is
and cardiovascular disease has been described in individ-also a growing body of data that support the notion that
uals with essential hypertension [7–12]. A number ofthese same groups of patients have an increased risk for
cross sectional studies of microalbuminuric patients withdevelopment of progressive renal injury and that lipids
essential hypertension have also suggested that theseare an independent risk factor for this event. Unfortu-
patients may be at greatest risk for more rapid loss ofnately, pharmacological interventional studies designed
renal function over time [13–15]. In both diabetic andto reduce the risk of dyslipidemia on cardiovascular and
essential hypertension patients with microalbuminuria,renal diseases are only now being developed.
the presence of multiple metabolic abnormalities hasDuring the past decade, considerable progress has
been recently identified. Paramount among these is thebeen made in the clinical and experimental understand-
presence of insulin resistance and dyslipidemia in con-ing of the mechanisms of progressive renal disease. Hy-
junction with abnormalities of the coagulation system.pertension, proteinuria and dyslipidemia have been iden-
tified as independent risk factors for progressive loss of
Essential hypertension and microalbuminuriarenal function. In humans, pharmacological treatments
In a study of 11,343 nondiabetic hypertensive subjects,to modify blood pressure or proteinuria have now been
microalbuminuria was present in approximately 30%. Ashown to have beneficial effects on rates of loss of renal
constellation of abnormalities has been seen in thesefunction. It remains unclear if reduction in circulating
patients including loss of normal diurnal variation in blood
pressure, loss of salt sensitivity, reduced Na1/Li1 counter-
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von Willebrand factor, reduced plasminogen activating short duration to feel confident about the results. None-
theless, these studies support the notion that use of lipid-factor and increased renin levels [8–12, 16–19]. In addi-
lowering treatments have an additive effect to antihyper-tion, dyslipidemia manifest by increased apolipoprotein
tensive therapy in preserving renal function [26].B-containing lipids and reduced high density lipopro-
teins are frequently observed. Triglyceride levels are
Chronic renal insufficiencymost frequently elevated and recently, increased lipopro-
Alterations in the levels and composition of lipids intein(a) levels have been described. The linkage between
patients with reduced renal function are common [27].dyslipidemia and microalbuminuria is not completely un-
Characteristically, they demonstrate a moderate increasederstood and is not explained by obesity or increased
in apolipoprotein B-containing lipoproteins of very lowbody mass. A more likely explanation is that this meta-
and low densities, and reduced levels and abnormal com-bolic derangement is related to the insulin resistance
position of apolipoprotein A-containing lipoproteins ofand consequent hyperinsulinemia seen in this unique
high densities. In addition, triglyceride enrichment ofsubpopulation of patients with essential hypertension.
the apolipoprotein B-containing lipids has been recentlyThe clinical ramifications of microalbuminuria have
identified as an important abnormality that correlatesindicated a significant increase in the cardiovascular
with progression of renal disease. The presence of smallevent rate and mortality in these patients [7–12]. In a
dense, triglyceride-enriched particles is also a major risksecondary analysis of the Multiple Risk Factor Interven-
factor involved in cardiovascular disease. This coupledtion Trial, the presence of minimal proteinuria conferred
with reduced high density lipoprotein is a highly athero-nearly a 2.5-fold greater risk for cardiovascular morbid
genic duet. The mechanisms for development of theseevents, even after adjustment for the usual risks for car-
abnormalities are complex and incompletely understood.diovascular disease such as age, cholesterol, blood pres-
Clearly, proteinuria is an important factor that is in-sure, smoking and degree of renal insufficiency [12]. Re-
volved in stimulating hepatic production of various lipo-cent studies in an older Caucasian population have
proteins, particularly apolipoprotein B-containing lipids.demonstrated that the presence of microalbuminuria
In addition, insulin resistance, which develops early inalso predicts the extent and severity of angiographically
the course of renal insufficiency, may have importantdemonstrable coronary artery disease [19].
effects on lipid metabolism possibly similar to that ob-
served in diabetes and in certain patients with essentialDiabetes mellitus and microalbuminuria
hypertension. A number of large trials have demon-The presence of microalbuminuria in patients with
strated that these lipid abnormalities are independent
type 1 and type 2 diabetes mellitus is a useful marker variables for the rate of loss of renal function [28]. Unfor-
for those patients at greatest risk for the development tunately, no lipid interventional trials have been per-
of microvascular and macrovascular disease [1, 2, 5, 6, formed in this population to see if either cardiovascular
20, 21]. As discussed above, these individuals display a or renal death can be reduced.
constellation of metabolic abnormalities including dys-
lipidemia, hypertension, abnormalities in coagulation, Congenital abnormalities of lipids associated with
and insulin resistance. The finding of an increased extent renal disease
and severity of angiographically demonstrable coronary At least two primary lipid disorders have been associ-
artery disease in older, microalbuminuric, type 2 diabetic ated with renal disease. Patients with a deficiency in
individuals is consistent with the notion of a dramatic lecithin-cholesterol acyltransferase develop large lipid-
clustering of risk factors for vascular disease [19]. Unfor- laden lipoproteins, glomerular lipid deposits and eventu-
tunately, few interventional studies designed to modify ally renal failure associated with glomerulosclerosis.
cardiovascular risks in the diabetic patient have been More recently, abnormalities in apolipoprotein E have
performed. In the Scandinavian Simvastatin Survival been described, mostly in Japanese patients, with a dis-
Study, type 2 diabetic subjects were shown to have a 2.5- tinct form of progressive renal disease. Since the major
fold greater risk for coronary artery disease than the function of apolipoprotein E is to remove apolipoprotein
nondiabetic study participants [22]. Treatment of the B containing particles by receptor-mediated endocytosis,
dyslipidemia significantly reduced the risk of coronary genetic or acquired mutations leading to impairment of
heart disease events [22, 23]. this important function would be expected to be associ-
With regard to microvascular disease, a number of ated with extensive macrovascular and microvascular
cross-sectional and prospective longitudinal studies have disease [29–32]. Indeed, this appears to be the case in
demonstrated that dyslipidemia, particularly elevated the reports to date. A better understanding of these
cholesterol levels, is an identifiable risk factor for loss abnormalities will hopefully provide a more targeted
of renal function on both univariate and multivariate approach to the treatment of these patients, as well as
analyzes [24, 25]. However, few interventional trials have a broader understanding of the factors that contribute
to progressive vascular and renal disease.been performed and are usually under-powered or of
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MECHANISMS OF LIPID INJURY: increase release of renin from juxtaglomerular cells [37].
Reduction in endothelial-derived relaxing factor or nitricEXPERIMENTAL INSIGHTS
oxide also has been reported. These alterations in thePre-clinical data
balance of vasoactive substances favors enhanced vaso-
A variety of experimental studies have lent credence constriction. Of note is that the HMG-CoA reductase
to the notion that dyslipidemia contributes to kidney inhibitors appear, in man, to normalize this vascular reac-
injury [32]. A high saturated fat diet or a diet enriched tivity abnormality. Thus, an intricate relationship exists
in cholesterol has been shown to enhance the degree of between hemodynamic factors that govern vascular tone
renal injury in experimental models of renal disease. The and metabolic factors that govern circulating lipids.
most compelling data come from a number of studies
utilizing different classes of lipid-lowering agents to re- Modification of inflammatory responses to renal injury
duce circulating lipids. In all of these investigations re- by lipid lowering agents
duction of lipids was associated with improvement in As suggested by the in vivo studies, it is now apparent
structural damage to glomeruli and to the interstitium. that the HMG-CoA reductase inhibitors have a number
These effects were associated with improvement in renal of important effects on cell processes involved in the
function and were observed to occur even after renal inflammatory response [37, 38]. It has also become evi-
disease was present [32]. These effects were seen in a dent that HMG-CoA reductase inhibitors reduce pro-
variety of different models of progressive renal disease duction of molecules involved in fibrogenesis [39].
and in some studies, have been shown to have an additive HMG-CoA reductase inhibitors reversibly inhibit the
effect to blockade of the renin angiotensin system [33]. proliferation of mesangial, vascular smooth muscle cells
In some of these studies in which cholesterol levels were and tubular epithelial cells to various mitogenic sub-
not profoundly elevated, HMG-CoA reductase inhibi- stances such as platelet-derived growth factor and insu-
tors reduced the degree of vascular and tubulointerstitial lin-like growth factor [37, 40–42]. Apoptosis also is aug-
injury [32]. These studies suggested that this class of mented by HMG-CoA reductase inhibition, and this
agents might have biological effects on the response to effect is reversible in the presence of mevalonate [37,
injury in addition to their lipid-lowering capabilities. 43]. This early metabolite of acetyl coenzyme A is an
important product of HMG-CoA reductase and is essen-Mechanisms of lipid injury
tial for the progression of the cell cycle [44].
The mechanisms whereby lipids contribute to vascular Macrophages play an important role in the process of
and renal injury are incompletely understood. Nonethe- injury and repair in the kidney. Their recruitment de-
less, a number of important effects of lipids on vascular, pends upon the expression and production of a number
mesangial and tubular cells have been identified. Foam of cytokines that allow for the adhesion, migration and
cells, which are believed to result from nonreceptor- maturation of these inflammatory cells from the vascula-
mediated uptake of modified lipoproteins by macro- ture to glomeruli or interstitium. Mesangial and vascular
phages, are frequently found in segments of glomeruli smooth muscle cells produce various cytokines involved
undergoing sclerosis and in the interstitial compartment in macrophage biology. Recent studies have shown that
of diseased kidneys [34]. Both macrophages as well as HMG-CoA reductase inhibitors can reduce mesangial
mesangial cells may oxidize lipoproteins, and these modi- and smooth muscle cell expression and production of
fied lipoproteins have been demonstrated to be present monocyte chemoattractant protein-1 and macrophage-
in glomeruli and interstitial regions [35]. Mesangial and colony stimulating factor (M-CSF) as well as vascular
tubular cells can produce reactive oxygen species, partic- cell adhesion molecule-1 and intracellular adhesion mol-
ularly superoxide, when exposed to a variety of factors ecule-1, which are integrin adhesion molecules involved
including angiotensin II and platelet-derived growth fac- in monocyte adherence to endothelial and mesangial
tor [36]. Oxidized low-density lipoproteins (LDLs) have cells [38, 45, 46]. These in vitro effects have in vivo conse-
been shown to stimulate inflammatory and fibrogenic quences in that HMG-CoA reductase inhibitors reduced
cytokine production and to cause increased cell apopto- glomerular influx of macrophages and this was associated
sis [37]. These modified lipoproteins also increase pro- with a reduction in indices of glomerular injury.
duction of reactive oxygen species, thereby creating a In the process of intracellular cholesterol metabolism
self-perpetuating mechanism for formation of these a variety of intermediate products are formed by a pro-
highly reactive lipids. The consequences of these events gressive elongation of carbon fragments. These interme-
are an increase in macrophage influx and increased pro- diates are called nonsterol isoprenoids and have been
duction of various matrix proteins and collagens as well shown to be critical in prenylation of small intracellular
as increased cell loss. These oxidized LDL particles have proteins such as p21ras. Two isoprenoid metabolites de-
been shown to also increase production of vasoactive rived from mevalonate, farnesyl pyrophosphate and ger-
anylgeranyl pyrophosphate, have been shown to be indis-substances such as endothelin and thromboxane, and to
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non-insulin-dependent diabetes. A ten-year follow-up study of 503pensable anchors of small G proteins such as p21ras, that
patients. Diabetes Med 5:126–134, 1988
allow these proteins to bind to cell membranes [18, 47]. 7. Collins VR, Dowse GK, Finch CF, Zimmet PZ, Linnane AW:
Binding of many growth factors to their receptor induces Prevalence and risk factors for micro- and macroalbuminuria in
diabetic subjects and entire population of Nauru. Diabetes 38:1602–p21ras activation and subsequent activation of Raf, mito-
1610, 1989
gen-activated protein kinase–extracellular signal-related 8. Gerber LM, Shmukler C, Alderman MH: Differences in urinary
protein (MEK), and the mitogen-activated kinase cas- albumin excretion rate between normotensive and hypertensive
white and non-white subjects. Arch Intern Med 152:373–377, 1992cade. In the nucleus, transcription factors, such as acti-
9. D’Agostino RB, Kannel WB, Stepanians MN, D’Agostino LC:
vated protein-1, nuclear factor-kB, nuclear factor inter- Efficacy and tolerability of lovastatin in hypercholesterolemia in
leukin-6, and early response gene ERG-1 are induced, patients with systemic hypertension. Am J Cardiol 71:82–87, 1993
10. Winocour PH, Harland JO, Millar JP, Laker MF, Alberti KG:as well as early response genes and subsequent cell prolif-
Microalbuminuria and associated cardiovascular risk factors in the
eration or differentiation then occurs. HMG-CoA reduc- community. Atherosclerosis 93:71–81, 1992
11. Cerasola G, Cottone S, Mule G, Nardi E, Mangano MT, An-tase inhibitors reversibly blocked the expression of two
dronico G, Contorno A, Li Vecchi M, Gaglione P, Renda F,of these early response genes, c-fos and c-jun, in conjunc-
Piazza G, Volpe V, Lisi A, Ferrara L, Panepinto N, Riccobene
tion with membrane-bound p21ras reduction [18, 48]. R: Microalbuminuria, renal dysfunction and cardiovascular compli-
cation in essential hypertension. J Hypertens 14:915–920, 1996The HMG-CoA reductase inhibitors also influence nu-
12. Grimm RH, Svendsen KH, Kasiske BL, Keane WF, Wahi M:clear events involved in the cell cycle in mesangial and
Proteinuria is a risk factor for mortality over 10 years of follow-
smooth muscle vascular cells. Reduced DNA synthesis up. The MRFIT Research Group. Kidney Int 52 (Suppl. 63):S-10–
S-14, 1997was associated with an increase in the cyclin-dependent
13. Bigazzi R, Bianchi S, Baldari D, Campese VM: Microalbuminu-kinase inhibitor p27Kip1 and a suppression of cyclin D1
ria predicts cardiovascular events and renal insufficiency in patients
and E expression [18, 49–51]. These effects on nuclear with essential hypertension. J Hypertens 16:1325–1333, 1998
14. Schmieder RE, Veelken R, Gatzka CD, Ruddle H, Schachingerevents may be partly explained by the observation that
H: Predictors for hypertensive nephropathy: results of seven yearsisoprenylation of p21RhoA and p21RhoB with geranyl-
of follow-up in essential hypertension. J Hypertens 13:357–365,
geranyl pyrophosphate is inhibited. These factors are 1994
15. Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Gar-essential for p27Kip1 degradation and subsequent pro-
cia Robles R, Rodicio JL: Blood pressure and renal function:gression from G1 to S phase of the cell-proliferation cycle
therapeutic implications. J Hypertens 14:1259–1263, 1996
[50, 51]. Thus, HMG-CoA reductase inhibitors seem not 16. Bianchi S, Bigazzi R, Baldari G, Sgherri G, Campese VM: Diur-
only to exert their beneficial effects on progressive renal nal variation of blood pressure and microalbuminuria in essential
hypertension. Am J Hypertens 7:23–29, 1994and vascular injury by reducing circulating lipids, but also
17. Equiluz-Bruck S, Schnack C, Kopp HP, Schernthaner G: Non-by modulating small G protein isoprenylation involved in dipping of nocturnal blood pressure is related to urinary albumin
early gene products, transcription factors, and modifying excretion rate in patients with type 2 diabetes mellitus. Am J
Hypertens 9:1139–1143, 1996cell-cycle regulatory proteins.
18. Baldoncini R, Desideri G, Bellini C, Valenti M, De Mattia
G, Santucci A, Ferri C: High plasma renin activity is combined
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